Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  McArt, Darragh G ^a   Zhang, Shu Dong ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORPROMAZINE; DILAZEP; DIPHEMANIL METHYLSULFATE; FLUPHENAZINE; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; LETROZOLE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOTHIAZINE DERIVATIVE; RESVERATROL; RETINOIC ACID; RILUZOLE; SOLASODINE; SULFAMETHOXAZOLE; TRANYLCYPROMINE; TRICHOSTATIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL PROLIFERATION; GENE EXPRESSION; GENE SIGNATURE PERTUBATION; GENETIC DATABASE; SCORING SYSTEM; TREATMENT INDICATION; UTERINE CERVIX CANCER; BREAST TUMOR; DRUG DEVELOPMENT; FACTUAL DATABASE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; UTERINE CERVIX TUMOR;

BREAST NEOPLASMS; DATABASES, FACTUAL; DRUG DISCOVERY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; UTERINE CERVICAL NEOPLASMS;

EID: 79551622693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016382     Document Type: Article

References (65)

1. Smalley JL, Gant TW, Zhang SD (2010) Application of connectivity mapping in predictive toxicology based on gene-expression similarity. Toxicology 268: 143-146.
2. Lamb J (2007) The connectivity map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60.
3. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
4. Gullans SR (2006) Connecting the dots using gene-expression profiles. N Engl J Med 355: 2042-2044.
5. Zhang SD, Gant T (2008) A simple and robust method for connecting smallmolecule drugs using gene-expression signatures. BMC Bioinformatics 9: 258.
6. Zhang SD, Gant T (2009) sscmap: An extensible java application for connecting small-molecule drugs using gene-expression signatures. BMC Bioinformatics 10: 236.
7. Feng C, Araki M, Kunimoto R, Tamon A, Makiguchi H, et al. (2009) Gemtrend: a web tool for gene expression data mining toward relevant network discovery. BMC Genomics 10: 411.
8. De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, et al. (2009) Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clinical Cancer Research 15: 3690-3696.
9. Braconi C, Meng F, Swenson E, Khrapenko L, Huang N, et al. (2009) Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer 115: 3738-3748.
10. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences 107: 14621-14626.
11. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, et al. (2010) Druginduced regulation of target expression. PLoS Comput Biol 6: e1000925.
12. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: Ncbi gene expression and hybridization array data repository. Nucl Acids Res 30: 207-210.
13. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, et al. (2008) Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. Genes, Chromosomes and Cancer 47: 755-765.
14. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, et al. (2008) Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes, Chromosomes and Cancer 47: 8-20.
15. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, et al. (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics 17: 813-826.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biology 5: R80.
17. Mayani H, Flores-Figueroa E, Chávez-González A (2009) In vitro biology of human myeloid leukemia. Leukemia Research 33: 624-637.
18. Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology 2008: 400-411.
19. Waggoner SE (2003) Cervical cancer. The Lancet 361: 2217-2225.
20. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology 189: 12-19.
21. Hiscox S, Davies EL, Barrett-Lee P (2009) Aromatase inhibitors in breast cancer. Maturitas 63: 275-279.
22. Sabnis GJ, Jelovac D, Long B, Brodie A (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65: 3903-3910.
23. Klopper J, Sharma V, Berenz A, Hays W, Loi M, et al. (2009) Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Molecular Cancer 8: 16.
24. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, et al. (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (mmp)-2, and mmp-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66: 10357-10364.
25. Sava G, Perissin L, Zorzet S, Piccini P, Giraldi T (1989) Antimetastatic action of the prostacyclin analog iloprost in the mouse. Clinical and Experimental Metastasis 7: 671-678.
26. Friedman M, Henika PR, Mackey BE (2003) Effect of feeding solanidine, solasodine and tomatidine to non-pregnant and pregnant mice. Food and Chemical Toxicology 41: 61-71.
27. Rybaczyk L, Bashaw M, Pathak D, Huang K (2008) An indicator of cancer: downregulation of monoamine oxidase-a in multiple organs and species. BMC Genomics 9: 134.
28. Cass CE, King KM, Montano JT, Janowska-Wieczorek A (1992) A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res 52: 5879-5886.
29. Sayan BS, Yang AL, Conforti F, Bernardini S, Tucci P, et al. (2010) Induction of tap63 by histone deacetylase inhibitors. Biochemical and Biophysical Research Communications 391: 1748-1751.
30. Gil-Ad I, Shtaif B, Levkovitz Y, Nordenberg J, Taler M, et al. (2006) Phenothiazines induce apoptosis in a b16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncology Reports 15: 107-112.
31. 12,14-prostaglandin j2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of dna-binding domain. Cancer Res 67: 2595-2602.
32. Do B, Goulay-Dufaÿ S, Hoang ML, Adoui N, Graffard H, et al. (2007) Sensitive quantification of diphemanil methyl sulphate in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 845: 104-108.
33. Akamatsu K, Shibata Y MA; Ito, Sohma Y, Azuma H, Otsuki Y (2009) Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress. Anticancer Research 29: 2195-2204.
34. Bodey GP KM Grose WE (1982) Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 4: 579-585.
35. Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, et al. (2010) Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. International Journal of Cancer 126: 28-40.
36. Seufferlein T, Seckl MJ, Schwarz E, Beil M, v Wichert G, et al. (2002) Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer 86: 1188-1196.
37. Lee MH, Choi BY, Kundu JK, Shin YK, Na HK, et al. (2009) Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: Eukaryotic elongation factor 1a2 as a potential target. Cancer Res 69: 7449-7458.
38. Teranishi F, Takahashi N, Gao N, Akamo Y, Takeyama H, et al. (2009) Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Science 100: 770-777.
39. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, et al. (2009) Trichostatin a sensitizes human ovarian cancer cells to trail-induced apoptosis by downregulation of c-flipl via inhibition of egfr pathway. Biochemical Pharmacology 77: 1328-1336.
40. Roumier C, Cheok MH (2009) Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 10: 1839-1851.
41. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, et al. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028.
42. Huang M, Ye Y, Chen S, Chai J, Lu J, et al. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
43. Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, et al. (1999) Regulation of aml2/cbfa3 in hematopoietic cells through the retinoic acid receptor adependent signaling pathway. Journal of Biological Chemistry 274: 21651-21658.
44. Cheng CK, Li L, Cheng SH, Lau KM, Chan NPH, et al. (2008) Transcriptional repression of the runx3/aml2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. Blood 112: 3391-3402.
45. McNamara S, Miller WH (2008) Expanding the use of retinoids in acute myeloid leukemia: Spotlight on bexarotene. Clinical Cancer Research 14: 5311-5313.
46. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, et al. (2008) A phase i study of bexarotene, a retinoic x receptor agonist, in non-m3 acute myeloid leukemia. Clinical Cancer Research 14: 5619-5625.
47. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, et al. (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. Cancer Prev Res 1: 349-356.
48. Wu C, Wang S, Wang F, Chen Q, Peng S, et al. (2009) Increased frequencies of t helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clinical & Experimental Immunology 158: 199-204.
49. Borgundvaag B, Kudlow J, Mueller S, George S (1992) Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-alpha gene expression and growth in anterior pituitary, but not in uterus. Endocrinology 130: 3453-3458.
50. Gariglio P, Gutirrez J, Corts E, Vzquez J (2009) The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Archives of Medical Research 40: 449-465.
51. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, et al. (2009) Combination of proteasome and hdac inhibitors for uterine cervical cancer treatment. Clinical Cancer Research 15: 570-577.
52. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through ppar[γ]. Nat Med 4: 1046-1052.
53. del Campo JM, Prat A, Gil-Moreno A, Prez J, Parera M (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110: S72-S76.
54. Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, et al. (2010) Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Letters 292: 54-63.
55. Keely SJ, Calandrella SO, Barrett KE (2000) Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in t(84) cells is mediated by intracellular ca(2+), pyk-2, and p60(src). Journal of Biological Chemistry 275: 12619-12625.
56. Calle EE, Mervis CA, Thun MJ, Rodriguez C, Wingo PA, et al. (1996) Diethylstilbestrol and risk of fatal breast cancer in a prospective cohort of us women. Am J Epidemiol 144: 645-652.
57. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, et al. (2006) Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiology Biomarkers & Prevention 15: 1509-1514.
58. Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C (2008) Does breast cancer start in the womb? Basic & Clinical Pharmacology & Toxicology 102: 125-133.
59. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Yuan HJ, et al. (2008) Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic & Clinical Pharmacology & Toxicology 103: 336-341.
60. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
61. Schroder O, Yudina Y, Sabirsh A, Zahn N, Haeggstrom JZ, et al. (2006) 15-deoxy-Delta12,14-prostaglandin j2 inhibits the expression of microsomal prostaglandin e synthase type 2 in colon cancer cells. J Lipid Res 47: 1071-1080.
62. Eads D, Hansen R, Oyegunwa A, Cecil C, Culver C, et al. (2009) Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. Journal of Inflammation 6: 2.
63. Wendeburg L, de Oliveira A, Bhatia H, Candelario-Jalil E, Fiebich B (2009) Resveratrol inhibits prostaglandin formation in il-1beta-stimulated sk-n-sh neuronal cells. Journal of Neuroinflammation 6: 26.
64. Bilotas M, Meresman G, Stella I, Sueldo C, Barañao RI (2010) Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertility and Sterility 93: 2513-2518.
65. Han M, Kim JY, Park JE, Kim JM, Lee KS (2008) Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin e2. European Journal of Obstetrics & Gynecology and Reproductive Biology 138: 83-88.